Home › Companies › GERN

Geron

GERN Lead: Approved

Oncology Nucleic Acid

Most recent annual filing: 2026-03-15

Pipeline (3 active programs)

RYTELO

imetelstat

Nucleic Acid Target: telomerase

Myelodysplastic Syndromes Approved intravenous
Myelofibrosis Phase 3 intravenous

imetelstat

Nucleic Acid Target: telomerase

Acute Myeloid Leukemia Phase 2